Please assess the completion status of the following clinical trial:

Trial Title: Safety Study of Recombinant Human Alpha-mannosidase for the Treatment of Patients With Alpha-mannosidosis

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~1. The patient must have a confirmed diagnosis of alpha-mannosidosis as defined by alpha-mannosidase activity \< 10% of normal activity in blood leukocytes~2. The patient must have an age at the time of screening ≥ 5 year and ≤ 20 years~3. The patient must have physical ability to perform 6-minutes walk test (6MWT), 3 minute-stair climb test (3MSCT) and pulmonary lung function test (spirometry, body plethysmography).~4. The patient must have the ability to mentally cooperate in the cognitive and motor function tests~5. The patient must have the ability to hear and follow a request. Hearing aids can be worn.~6. Patient or patient's legally authorized guardian(s) must provide signed, informed consent prior to performing any study-related activities (trial-related activities are any procedures that would not have been performed during normal management of the subject)~7. The patient and his/her guardian(s) must have the ability to comply with the protocol~Exclusion Criteria:~1. The patient cannot walk without support.~2. Presence of known chromosomal abnormality and syndromes affecting psychomotor development, other than alpha-mannosidosis~3. History of bone marrow transplantation~4. Presence of known clinically significant cardiovascular, hepatic, pulmonary or renal disease or other medical conditions that, in the opinion of the Investigator, would preclude participation in the trial~5. Presence of an ECHO with abnormalities within half a year that, in the opinion of the Investigator, would preclude participation in the trial~6. Any other medical condition or serious intercurrent illness, or extenuating circumstance that, in the opinion of the investigator, would preclude participation in the trial~7. Pregnancy~8. Psychosis within the last 3 months

- Gender: ALL
- Minimum Age: 5 Years
- Maximum Age: 20 Years
- Healthy Volunteers: f

Study Arms:
- Lamazym 6.25 (Type: EXPERIMENTAL): None
- Lamazym 12.5 (Type: EXPERIMENTAL): None
- Lamazym 25 (Type: EXPERIMENTAL): None
- Lamazym 50 (Type: EXPERIMENTAL): None
- Lamazym 100 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).